January 2015

New Product - Zerbaxa

Zerbaxa (ceftolozane + tazobactam) is an antibacterial composed of a cephalosporin (ceftolozane) and a beta‑lactamase inhibitor (tazobactam). Zerbaxa (ceftolozane/tazobactam) is indicated for the treatment of the following infections in adults suspected or proven to be caused by designated susceptible microorganisms: complicated intra-abdominal infections in combination with metronidazole; complicated urinary tract infections, including pyelonephritis. Zerbaxa is contraindicated in patients with hypersensitivity to members of the cephalosporin class, or other members of the beta‑lactam class. Zerbaxa is available as a powder for infusion in a pack of 10 vials each containing ceftolozane (as sulfate) 1000 mg and tazobactam (as sodium) 500 mg respectively.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au